Physician profile
Jonathan T Gully
NPI 1740574342
$5,443.66
in general payments reported to CMS, 2019-2025
40 companies · $26.01 in 2025
The $26.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $567 · 2021: $1,143 · 2022: $1,096 · 2023: $1,106 · 2024: $220 · 2025: $26.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $758.15 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $652.97 | 2019-2023 | |
| Lilly USA, LLC | $541.72 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $436.77 | 2019-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $400.07 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.70 | 2019-2023 | Jardiance |
| Pfizer INC. | $275.13 | 2019-2024 | |
| Amarin Pharma, INC. | $231.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $221.31 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $179.10 | 2019-2023 | Steglatro, Belsomra |
| Amgen INC. | $161.53 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.86 | 2019-2023 | Xifaxan |
| Corium, LLC | $118.69 | 2022-2023 | Azstarys |
| Astellas Pharma US INC | $90.30 | 2020-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $87.31 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $80.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $74.26 | 2021 | |
| Allergan, INC. | $64.89 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.36 | 2019-2022 | |
| Dexcom, INC. | $58.35 | 2021-2024 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $43.35 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bayer Healthcare Pharmaceuticals INC. | $41.89 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $40.02 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $36.86 | 2019-2020 | |
| Genentech USA, INC. | $34.62 | 2020-2021 | |
| Esperion Therapeutics, INC. | $33.74 | 2020 | |
| Imperative Care, INC | $31.90 | 2024 | Symphony Catheter |
| Eyevance Pharmaceuticals LLC | $29.16 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.56 | 2022 | |
| Boston Scientific Corporation | $26.41 | 2019 | |
| Hikma Pharmaceuticals USA | $26.00 | 2019-2021 | |
| Lundbeck LLC | $21.90 | 2023 | Vyepti |
| Xeris Pharmaceuticals, INC. | $19.98 | 2023 | Gvoke Hypopen |
| Circassia INC. | $19.05 | 2019 | |
| Dynavax Technologies Corporation | $15.51 | 2023 | Heplisav-B |
| Renalytix Ai, INC. | $15.49 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2022 | |
| Philips North America LLC | $14.73 | 2024 | (Ck7) Extended Holter |
| Aytu Biopharma, INC. | $13.72 | 2019 | |
| Nabriva Therapeutics, Plc | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.